Key Points
- HealthEquity EVP Sunil Rajasekar sold 108 shares at an average price of $105.60, totaling $11,404.80 and reducing his holdings by 0.20% to 53,297 shares.
- HealthEquity reported quarterly EPS of $1.24, exceeding estimates of $1.19, while revenue reached $350.73 million and increased 95.5% year over year.
- The stock opened at $93.07, and analysts maintain a “Moderate Buy” consensus with an average price target of $112.20; institutional investors own 99.55% of shares.
HealthEquity, Inc. (NASDAQ:HQY - Get Free Report) EVP Sunil Rajasekar sold 108 shares of the business's stock in a transaction on Monday, August 24th. The stock was sold at an average price of $105.60, for a total transaction of $11,404.80. Following the completion of the transaction, the executive vice president directly owned 53,297 shares in the company, valued at $5,628,163.20. This trade represents a 0.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Sunil Rajasekar also recently made the following trade(s):
- On Thursday, October 15th, Sunil Rajasekar bought 108 shares of HealthEquity stock. The shares were bought at an average price of $90.33 per share, with a total value of $9,755.64.
HealthEquity Price Performance
Shares of NASDAQ:HQY opened at $93.07 on Tuesday. The firm has a market cap of $7.70 billion, a price-to-earnings ratio of 33.60, a P/E/G ratio of 1.45 and a beta of 0.24. The firm has a fifty day moving average price of $95.80 and a 200 day moving average price of $91.53. HealthEquity, Inc. has a fifty-two week low of $72.76 and a fifty-two week high of $107.62. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.99 and a current ratio of 2.99.
HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings results on Thursday, August 27th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.19 by $0.05. The company had revenue of $350.73 million for the quarter, compared to the consensus estimate of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The firm's quarterly revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, sell-side analysts expect that HealthEquity, Inc. will post 3.93 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in HealthEquity during the second quarter valued at $1,018,621,000. William Blair Investment Management LLC bought a new position in HealthEquity during the second quarter valued at $160,158,000. Bank of America Corp DE bought a new position in HealthEquity during the second quarter valued at $103,573,000. Atalan Capital Partners LP purchased a new position in shares of HealthEquity in the 2nd quarter worth $82,667,000. Finally, Jupiter Topco LLC purchased a new position in shares of HealthEquity in the 2nd quarter worth $78,847,000. 99.55% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on the company. Citigroup restated a "market outperform" rating on shares of HealthEquity in a research report on Friday, August 28th. Raymond James Financial reaffirmed a "strong-buy" rating on shares of HealthEquity in a report on Thursday, September 3rd. Barclays boosted their target price on HealthEquity from $110.00 to $115.00 and gave the stock an "overweight" rating in a research report on Friday, September 18th. BTIG Research reissued a "buy" rating and set a $115.00 price target on shares of HealthEquity in a research note on Friday, August 28th. Finally, Telsey Advisory Group set a $111.00 price target on HealthEquity in a research note on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, HealthEquity presently has a consensus rating of "Moderate Buy" and an average target price of $112.20.
Get Our Latest Report on HQY
About HealthEquity
(
Get Free Report)
HealthEquity, Inc provides technology-enabled benefits administration and financial services that help employers and individuals manage tax-advantaged healthcare accounts. The company's offerings include health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), and other consumer-directed benefits.
In addition to account administration, HealthEquity provides payment cards, investment options for eligible account holders, employee engagement tools, and digital platforms for managing healthcare benefits.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
